ST. PAUL, Minn.--(BUSINESS WIRE)--MD Biosciences, a global biotechnology company focused in inflammations and neurology research, is expanding its line of arthritis and pain preclinical services with the addition of the CFA-induced monoarthritic pain model. The model offers advantages over traditional arthritis models in that disease develops in only one joint allowing a comparison to the healthy joint. The quantification of pain associated with arthritis can be useful in elucidating the mechanisms of arthritis as well as evaluating the efficacy of anti-arthritic drug compounds in the discovery phase.
